Hypofibrinogenemia caused by adrenocorticotropic hormone for infantile spasms: a case report
Atsushi Kamei1, Nami Araya1, Manami Akasaka1
1Department of Pediatrics, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Insights
Adrenocorticotropic hormone (ACTH) therapy for infantile spasms can cause hypofibrinogenemia, a dangerous drop in fibrinogen levels. Monitor fibrinogen during ACTH treatment and stop if levels fall below 60.0 mg/dL.
Area of Science:
- Pediatric Neurology
- Hematology
- Pharmacology
Background:
- Infantile spasms are a severe form of epilepsy in infants.
- Adrenocorticotropic hormone (ACTH) therapy is a common treatment for infantile spasms.
- Hypofibrinogenemia is a condition characterized by abnormally low levels of fibrinogen in the blood.
Observation:
- A 7-month-old boy undergoing ACTH therapy for infantile spasms developed hypofibrinogenemia.
- The patient's fibrinogen level dropped to 66.6 mg/dL, significantly below the reference range of 170-405 mg/dL.
- No clinical signs of bleeding diathesis were observed in the patient.
Findings:
- ACTH therapy can lead to a significant decrease in plasma fibrinogen levels.
- Hypofibrinogenemia during ACTH therapy may occur even without overt bleeding.
- Hemostatic levels of fibrinogen are considered to be above 60.0 mg/dL.
Implications:
- Plasma fibrinogen levels should be routinely monitored in patients receiving ACTH therapy.
- Discontinuation of ACTH therapy is recommended if fibrinogen levels fall below hemostatic levels or if bleeding tendencies arise.
- This case highlights a potential adverse effect of ACTH therapy that requires clinical vigilance and monitoring.
Abstract:
We report the case of a 7-month-old boy who developed hypofibrinogenemia (66.6 mg/dL; reference value, 170-405 mg/dL) during adrenocorticotropic hormone (ACTH) therapy for infantile spasms. Although the patient showed no clinical signs of a bleeding diathesis, we recommend that plasma fibrinogen levels should be monitored during ACTH therapy, which should be discontinued when fibrinogen levels fall below hemostatic levels (60.0mg/dL) or when bleeding tendencies are recognized.
More Related Videos
07:57Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Published on: August 25, 2022
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Related Concept Videos
Hypoglycemia and Glucagon
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Clot Retraction and Fibrinolysis
Cushing Syndrome II: Pathophysiology
Encephalitis l: Introduction
